PALATIN TECHNOLOGIES INC (PTN) Stock Price, Quote, News and Summary
NYSEARCA:PTN - American Stock Exchange - US6960775020 - Common Stock
PTN Quote and Key Statistics
PALATIN TECHNOLOGIES INC
NYSEARCA:PTN (1/21/2025, 8:22:13 PM)
After market: 1.12 +0.02 (+1.82%)1.1
+0.04 (+3.77%)
PTN Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -947.33% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
PTN Performance and Technical Analysis
PTN Ownership and Analysts
PTN Latest News and Analysis
PTN Stock Earnings: Palatin Techs Misses EPS for Q3 2024
PTN stock results show that Palatin Techs missed analyst estimates for earnings per share the third quarter of 2024.
Palatin stock plunges 40% on mixed Phase 3 data for dry eye drug (NYSE:PTN)
Palatin Technologies (PTN) stock plunged 40% Wednesday after the company said a Phase 3 pivotal study for its drug PL9643 failed to meet a co-primary endpoint. Read more here.
The 3 Best Penny Stocks to Buy in February 2024
With proposed FED rate cuts incoming, these are the penny stocks that are likely to see a spark into new rallies.
7 Analyst-Backed Stocks With Promising 10-Bagger Potential
Although true 10-baggers are by nature extremely difficult to come by, these analyst-backed stocks may offer a decent shot.
About PTN
Company Profile
Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. The company is headquartered in Cranbury, New Jersey and currently employs 30 full-time employees. The firm is engaged in developing medicines based on molecules that modulate the activity of the melanocortin receptor system. The Company’s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its new product development activities focus primarily on MC1r agonists, with the potential to treat inflammatory and autoimmune diseases, such as dry eye disease, which is also known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. The company is also developing peptides that are active at more than one melanocortin receptor, and MC4r peptide and small molecule agonists with potential utility in obesity and metabolic-related disorders, including rare disease and orphan indications. Its product candidates include PL9643 for dry eye disease and PL8177 for the treatment of ulcerative colitis.
Company Info
PALATIN TECHNOLOGIES INC
4B Cedar Brook Drive
Cranbury NEW JERSEY 08512 US
CEO: Carl Spana
Employees: 30
Company Website: https://www.palatin.com/
Investor Relations: http://www.palatin.com/investors/overview/
Phone: 16094952200
PTN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.06 | 305.03B | ||
| AMGN | AMGEN INC | 14.3 | 147.72B | ||
| GILD | GILEAD SCIENCES INC | 20.98 | 115.85B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 839 | 110.19B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.14 | 75.58B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.71B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.18B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.26B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.28B | ||
| NTRA | NATERA INC | N/A | 22.11B | ||
| BIIB | BIOGEN INC | 8.63 | 20.54B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.16 | 16.43B |